Longitudinal associations between exercise and biomarkers in autosomal dominant Alzheimer’s disease

by Clinical Neuropsychologist | Thursday, September 26, 2024 | Dementia

Abstract INTRODUCTION We investigated longitudinal associations between self-reported exercise and Alzheimer’s disease (AD)-related biomarkers in individuals with autosomal dominant AD (ADAD) mutations. METHODS Participants were 308 ADAD mutation carriers aged...

Effectiveness of electro‐acupuncture for cognitive improvement on Alzheimer’s disease quantified via PET imaging of sphingosine‐1‐phosphate receptor 1

by Clinical Neuropsychologist | Wednesday, September 25, 2024 | Dementia

Abstract INTRODUCTION Electro-acupuncture (EA) has demonstrated potential in improving mild-to-moderate dementia in clinics, but the underlying scientific target remains unclear. METHODS EA was administered to APP/PS1 Alzheimer’s disease (AD) mice, with...

MEDI1814 selectively reduces free Aβ42 in cerebrospinal fluid of non‐clinical species and Alzheimer’s disease patients

by Clinical Neuropsychologist | Wednesday, September 25, 2024 | Dementia

Abstract INTRODUCTION Small molecules and antibodies are being developed to lower amyloid beta (Aβ) peptides. METHODS We describe MEDI1814, a fully human high-affinity monoclonal antibody selective for Aβ42, the pathogenic self-aggregating species of Aβ. RESULTS...

Reversibility of cognitive worsening observed with BACE inhibitor umibecestat in the Alzheimer’s Prevention Initiative (API) Generation Studies

by Clinical Neuropsychologist | Wednesday, September 25, 2024 | Dementia

Abstract INTRODUCTION The Alzheimer’s Prevention Initiative (API) Generation Studies evaluated the BACE inhibitor umibecestat for Alzheimer’s disease (AD) prevention. The studies were terminated early, and the reversibility of umibecestat’s side...

A framework for translating tauopathy therapeutics: Drug discovery to clinical trials

by Clinical Neuropsychologist | Tuesday, September 24, 2024 | Dementia

Abstract The tauopathies are defined by pathological tau protein aggregates within a spectrum of clinically heterogeneous neurodegenerative diseases. The primary tauopathies meet the definition of rare diseases in the United States. There is no approved treatment for...

Ethnic differences in the prevalence of amyloid positivity and cognitive trajectories

by Clinical Neuropsychologist | Tuesday, September 24, 2024 | Dementia

Abstract INTRODUCTION We investigated the prevalence of amyloid beta (Aβ) positivity (+) and cognitive trajectories in Koreans and non-Hispanic Whites (NHWs). METHODS We included 5121 Koreans from multiple centers across South Korea and 929 NHWs from the...